David K Wallace1, Raymond T Kraker2, Sharon F Freedman3, Eric R Crouch4, Amit R Bhatt5, M Elizabeth Hartnett6, Michael B Yang7, David L Rogers8, Amy K Hutchinson9, Deborah K VanderVeen10, Kathryn M Haider1, R Michael Siatkowski11, Trevano W Dean2, Roy W Beck2, Michael X Repka12, Lois E Smith9, William V Good13, Lingkun Kong14, Susan A Cotter15, Jonathan M Holmes16. 1. Indiana University Department of Ophthalmology, Indianapolis. 2. Jaeb Center for Health Research, Tampa, Florida. 3. Duke Eye Center, Durham, North Carolina. 4. Eastern Virginia Medical School, Norfolk. 5. Texas Children's Hospital, Houston. 6. John A. Moran Eye Center, Salt Lake City, Utah. 7. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 8. Pediatric Ophthalmology Associates Inc, Columbus, Ohio. 9. Emory University School of Medicine, Atlanta, Georgia. 10. Boston Children's Hospital, Boston, Massachusetts. 11. Dean McGee Eye Institute, University of Oklahoma, Oklahoma City. 12. Wilmer Eye Institute, Baltimore, Maryland. 13. Smith-Kettlewell Eye Research Institute, San Francisco, California. 14. Baylor College of Medicine, Houston, Texas. 15. Southern California College of Optometry at Marshall B. Ketchum University, Fullerton. 16. Mayo Clinic, Rochester, Minnesota.
Abstract
Importance: Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk of neurodevelopmental delay. A much lower dose may be effective for ROP while reducing systemic risk. Previously, after testing doses of 0.25 mg to 0.031 mg, doses as low as 0.031 mg were found to be effective in small cohorts of infants. Objective: To find the lowest dose of intravitreous bevacizumab effective for severe ROP. Design, Setting, and Participants: Between April 2017 and May 2019, 59 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, dose de-escalation study. In cohorts of 10 to 14 infants, 1 eye per infant received 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreous bevacizumab. Diluted bevacizumab was prepared by individual research pharmacies and delivered using 300-µL syringes with 5/16-inch, 30-guage fixed needles. Analysis began July 2019. Interventions: Bevacizumab intravitreous injections at 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg. Main Outcomes and Measures: Success was defined as improvement by 4 days postinjection and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. Results: Fifty-five of 59 enrolled infants had 4-week outcomes completed; the mean (SD) birth weight was 664 (258) g, and the mean (SD) gestational age was 24.8 (1.6) weeks. A successful 4-week outcome was achieved for 13 of 13 eyes (100%) receiving 0.016 mg, 9 of 9 eyes (100%) receiving 0.008 mg, 9 of 10 eyes (90%) receiving 0.004 mg, but only 17 of 23 eyes (74%) receiving 0.002 mg. Conclusions and Relevance: These data suggest that 0.004 mg may be the lowest dose of bevacizumab effective for ROP. Further investigation is warranted to confirm effectiveness of very low-dose intravitreous bevacizumab and its effect on plasma vascular endothelial growth factor levels and peripheral retinal vascularization.
Importance: Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk of neurodevelopmental delay. A much lower dose may be effective for ROP while reducing systemic risk. Previously, after testing doses of 0.25 mg to 0.031 mg, doses as low as 0.031 mg were found to be effective in small cohorts of infants. Objective: To find the lowest dose of intravitreous bevacizumab effective for severe ROP. Design, Setting, and Participants: Between April 2017 and May 2019, 59 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, dose de-escalation study. In cohorts of 10 to 14 infants, 1 eye per infant received 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreous bevacizumab. Diluted bevacizumab was prepared by individual research pharmacies and delivered using 300-µL syringes with 5/16-inch, 30-guage fixed needles. Analysis began July 2019. Interventions: Bevacizumab intravitreous injections at 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg. Main Outcomes and Measures: Success was defined as improvement by 4 days postinjection and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. Results: Fifty-five of 59 enrolled infants had 4-week outcomes completed; the mean (SD) birth weight was 664 (258) g, and the mean (SD) gestational age was 24.8 (1.6) weeks. A successful 4-week outcome was achieved for 13 of 13 eyes (100%) receiving 0.016 mg, 9 of 9 eyes (100%) receiving 0.008 mg, 9 of 10 eyes (90%) receiving 0.004 mg, but only 17 of 23 eyes (74%) receiving 0.002 mg. Conclusions and Relevance: These data suggest that 0.004 mg may be the lowest dose of bevacizumab effective for ROP. Further investigation is warranted to confirm effectiveness of very low-dose intravitreous bevacizumab and its effect on plasma vascular endothelial growth factor levels and peripheral retinal vascularization.
Authors: Girija Natarajan; Seetha Shankaran; Tracy L Nolen; Amaanti Sridhar; Kathleen A Kennedy; Susan R Hintz; Dale L Phelps; Sara B DeMauro; Waldemar A Carlo; Marie G Gantz; Abhik Das; Rachel G Greenberg; Noelle E Younge; Joseph M Bliss; Ruth Seabrook; Pablo J Sánchez; Myra H Wyckoff; Edward F Bell; Betty R Vohr; Rosemary D Higgins Journal: Pediatrics Date: 2019-07-23 Impact factor: 7.124
Authors: Lingkun Kong; Amit R Bhatt; Ann B Demny; David K Coats; Alexa Li; Effie Z Rahman; O'Brian E Smith; Paul G Steinkuller Journal: Invest Ophthalmol Vis Sci Date: 2015-01-22 Impact factor: 4.799
Authors: David K Wallace; Raymond T Kraker; Sharon F Freedman; Eric R Crouch; Amy K Hutchinson; Amit R Bhatt; David L Rogers; Michael B Yang; Kathryn M Haider; Deborah K VanderVeen; R Michael Siatkowski; Trevano W Dean; Roy W Beck; Michael X Repka; Lois E Smith; William V Good; Mary Elizabeth Hartnett; Lingkun Kong; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Sharon F Freedman; Amra Hercinovic; David K Wallace; Raymond T Kraker; Zhuokai Li; Amit R Bhatt; Charline S Boente; Eric R Crouch; G Baker Hubbard; David L Rogers; Deborah VanderVeen; Michael B Yang; Nathan L Cheung; Susan A Cotter; Jonathan M Holmes Journal: Ophthalmology Date: 2022-06-01 Impact factor: 14.277
Authors: M Elizabeth Hartnett; David K Wallace; Trevano W Dean; Zhuokai Li; Charline S Boente; Eniolami O Dosunmu; Sharon F Freedman; Richard P Golden; Lingkun Kong; S Grace Prakalapakorn; Michael X Repka; Lois E Smith; Haibo Wang; Raymond T Kraker; Susan A Cotter; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2022-04-01 Impact factor: 8.253
Authors: Michael Simmons; Jingyun Wang; Joel N Leffler; Shanshan Li; Sarah E Morale; Angie de la Cruz; Eileen E Birch Journal: Transl Vis Sci Technol Date: 2021-04-01 Impact factor: 3.283
Authors: Dupe S Ademola-Popoola; Iretiola B Fajolu; Clare Gilbert; Bolutife A Olusanya; Oluwatoyin H Onakpoya; Chinyelu N Ezisi; Kareem O Musa; Robison Vernon Paul Chan; Valentina W Okeigbemen; Rilwan C Muhammad; Aeesha N J Malik; Adedayo O Adio; Olubunmi T Bodunde; Abdulkadir L Rafindadi; Tunji S Oluleye; Olukemi O Tongo; Sarat A Badmus; Olufunmilayo V Adebara; Tapas Ranjan Padhi; Beatrice N Ezenwa; Tokunbo S Obajolowo; Lateefat B Olokoba; Victoria A Olatunji; Yewande Olubunmi Babalola; Mary O Ugalahi; Adetunji Adenekan; Omotayo O Adesiyun; Jagdish Sahoo; Marilyn T Miller; Odarosa M Uhumwangho; Adeduntan S Olagbenro; Ebunoluwa A Adejuyigbe; Chinyere V C Ezeaka; Olugbenga Mokuolu; Tinuade A Ogunlesi; Olusoga B Ogunfowora; Isa Abdulkadir; Fatima L Abdullahi; Abosede T Fabiyi; Laila H L Hassan; Aderonke M Baiyeroju; Peace I Opara; Kehinde Oladigbolu; Augusta U Eneh; Bassey E Fiebai; Fatima A Mahmud-Ajeigbe; Elijah N Peter; Hawwa S Abdullahi Journal: BMJ Open Ophthalmol Date: 2021-08-23